Raymond James & Associates’s Allergan plc AGN.PRA Stock Holding History

Raymond James & Associates’s Portfolio AGN.PRA Stock Details AGN.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,164	Closed	-$682K	–	3662
2017 Q4	$682K	Sell	1,164 -9,988	-90%	-$6.45M	﹤0.01%	2359
2017 Q3	$8.23M	Buy	11,152 +147	+1%	+$122K	0.02%	848
2017 Q2	$9.55M	Buy	11,005 +6,205	+129%	+$5.2M	0.02%	720
2017 Q1	$4.07M	Buy	4,800 +1,307	+37%	+$1.08M	0.01%	1121
2016 Q4	$2.66M	Buy	3,493 +828	+31%	+$626K	0.01%	1320
2016 Q3	$2.19M	Buy	+2,665	New	+$2.3M	0.01%	1391

Other funds holding AGN.PRA

PWS

Peloton Wealth Strategists Indianapolis, Indiana $271M AUM 19.14% 1-Year Est. Return

Raymond James & Associates's AGN.PRA Position: Q1 2018 in Review

Raymond James & Associates sold out of Allergan plc (AGN.PRA) in Q1 2018, closing a stake of 1,164 shares — an estimated $682K sold.

Raymond James & Associates first reported a position in AGN.PRA in Q3 2016 and held it in 6 quarters. The position peaked at $9.55M in Q2 2017. 1 fund tracked by Wall St. Rank holds AGN.PRA as of Q1 2018.

Raymond James & Associates reported no remaining Allergan plc position as of Q1 2018 after selling out during the quarter.
Raymond James & Associates sold 1,164 Allergan plc shares in Q1 2018, an estimated $682K.
Raymond James & Associates first reported a position in Allergan plc in Q3 2016 and held it in 6 quarters.
Raymond James & Associates's Allergan plc position peaked at $9.55M in Q2 2017.
1 fund tracked by Wall St. Rank held Allergan plc as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.